Evidence for ordering of Alzheimer disease biomarkers

Clifford R Jr. Jack, Prashanthi D Vemuri, Heather J. Wiste, Stephen D. Weigand, Paul S. Aisen, John Q. Trojanowski, Leslie M. Shaw, Matthew A Bernstein, Ronald Carl Petersen, Michael W. Weiner, David S Knopman

Research output: Contribution to journalArticle

160 Citations (Scopus)

Abstract

Objective: To empirically assess the concept that Alzheimer disease (AD) biomarkers significantly depart from normality in a temporally ordered manner. Design: Validation sample. Setting: Multisite, referral centers. Participants: A total of 401 elderly participants in the Alzheimer's Disease Neuroimaging Initiative who were cognitively normal, who had mild cognitive impairment, or who had AD dementia. We compared the proportions of 3 AD biomarker values (the Aβ42 level in cerebrospinal fluid [CSF], the total tau level in CSF, and the hippocampal volume adjusted for intracranial volume [hereafter referred to as the adjusted hippocampal volume]) that were abnormal as cognitive impairment worsened. Cut points demarcating normal vs abnormal for each biomarker were established by maximizing diagnostic accuracy in independent autopsy samples. Main Outcome Measures: Three AD biomarkers (ie, the CSF Aβ42 level, the CSF total tau level, and the adjusted hippocampal volume). Results: Within each clinical group of the entire sample (n=401), the CSF Aβ42 level was abnormal more often than was the CSF total tau level or the adjusted hippocampal volume. Among the 298 participants with bothbaseline and 12-month data, the proportion of participants with an abnormal Aβ42 level did not change from baseline to 12 months in any group. The proportion of participants with an abnormal total tau level increased from baseline to 12 months in cognitively normal participants (P=.05) but not in participants with mild cognitive impairment or AD dementia. For 209 participants with an abnormal CSF Aβ42 level at baseline, the percentage with an abnormal adjusted hippocampal volume but normal CSF total tau level increased from baseline to 12 months in participants with mild cognitive impairment. No change in the percentage of MCI participants with an abnormal total tau level was seen between baseline and 12 months. Conclusions: A reduction in the CSF Aβ42 level denotes a pathophysiological process that significantly departs from normality (ie, becomes dynamic) early, whereas the CSF total tau level and the adjusted hippocampal volume are biomarkers of downstream pathophysiological processes. The CSF total tau level becomes dynamic before the adjusted hippocampal volume, but the hippocampal volume is more dynamic in the clinically symptomatic mild cognitive impairment and AD dementia phases of the disease than is the CSF total tau level.

Original languageEnglish (US)
Pages (from-to)1526-1535
Number of pages10
JournalArchives of Neurology
Volume68
Issue number12
DOIs
StatePublished - Dec 2011

Fingerprint

Cerebrospinal Fluid
Alzheimer Disease
Biomarkers
Alzheimer's Disease
Mild Cognitive Impairment
Neuroimaging
Autopsy
Referral and Consultation
Proportion
Dementia
Outcome Assessment (Health Care)
Cognitive Dysfunction

ASJC Scopus subject areas

  • Clinical Neurology
  • Arts and Humanities (miscellaneous)

Cite this

Evidence for ordering of Alzheimer disease biomarkers. / Jack, Clifford R Jr.; Vemuri, Prashanthi D; Wiste, Heather J.; Weigand, Stephen D.; Aisen, Paul S.; Trojanowski, John Q.; Shaw, Leslie M.; Bernstein, Matthew A; Petersen, Ronald Carl; Weiner, Michael W.; Knopman, David S.

In: Archives of Neurology, Vol. 68, No. 12, 12.2011, p. 1526-1535.

Research output: Contribution to journalArticle

Jack, Clifford R Jr. ; Vemuri, Prashanthi D ; Wiste, Heather J. ; Weigand, Stephen D. ; Aisen, Paul S. ; Trojanowski, John Q. ; Shaw, Leslie M. ; Bernstein, Matthew A ; Petersen, Ronald Carl ; Weiner, Michael W. ; Knopman, David S. / Evidence for ordering of Alzheimer disease biomarkers. In: Archives of Neurology. 2011 ; Vol. 68, No. 12. pp. 1526-1535.
@article{31924af1a8a74734b661d45426176b57,
title = "Evidence for ordering of Alzheimer disease biomarkers",
abstract = "Objective: To empirically assess the concept that Alzheimer disease (AD) biomarkers significantly depart from normality in a temporally ordered manner. Design: Validation sample. Setting: Multisite, referral centers. Participants: A total of 401 elderly participants in the Alzheimer's Disease Neuroimaging Initiative who were cognitively normal, who had mild cognitive impairment, or who had AD dementia. We compared the proportions of 3 AD biomarker values (the Aβ42 level in cerebrospinal fluid [CSF], the total tau level in CSF, and the hippocampal volume adjusted for intracranial volume [hereafter referred to as the adjusted hippocampal volume]) that were abnormal as cognitive impairment worsened. Cut points demarcating normal vs abnormal for each biomarker were established by maximizing diagnostic accuracy in independent autopsy samples. Main Outcome Measures: Three AD biomarkers (ie, the CSF Aβ42 level, the CSF total tau level, and the adjusted hippocampal volume). Results: Within each clinical group of the entire sample (n=401), the CSF Aβ42 level was abnormal more often than was the CSF total tau level or the adjusted hippocampal volume. Among the 298 participants with bothbaseline and 12-month data, the proportion of participants with an abnormal Aβ42 level did not change from baseline to 12 months in any group. The proportion of participants with an abnormal total tau level increased from baseline to 12 months in cognitively normal participants (P=.05) but not in participants with mild cognitive impairment or AD dementia. For 209 participants with an abnormal CSF Aβ42 level at baseline, the percentage with an abnormal adjusted hippocampal volume but normal CSF total tau level increased from baseline to 12 months in participants with mild cognitive impairment. No change in the percentage of MCI participants with an abnormal total tau level was seen between baseline and 12 months. Conclusions: A reduction in the CSF Aβ42 level denotes a pathophysiological process that significantly departs from normality (ie, becomes dynamic) early, whereas the CSF total tau level and the adjusted hippocampal volume are biomarkers of downstream pathophysiological processes. The CSF total tau level becomes dynamic before the adjusted hippocampal volume, but the hippocampal volume is more dynamic in the clinically symptomatic mild cognitive impairment and AD dementia phases of the disease than is the CSF total tau level.",
author = "Jack, {Clifford R Jr.} and Vemuri, {Prashanthi D} and Wiste, {Heather J.} and Weigand, {Stephen D.} and Aisen, {Paul S.} and Trojanowski, {John Q.} and Shaw, {Leslie M.} and Bernstein, {Matthew A} and Petersen, {Ronald Carl} and Weiner, {Michael W.} and Knopman, {David S}",
year = "2011",
month = "12",
doi = "10.1001/archneurol.2011.183",
language = "English (US)",
volume = "68",
pages = "1526--1535",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Evidence for ordering of Alzheimer disease biomarkers

AU - Jack, Clifford R Jr.

AU - Vemuri, Prashanthi D

AU - Wiste, Heather J.

AU - Weigand, Stephen D.

AU - Aisen, Paul S.

AU - Trojanowski, John Q.

AU - Shaw, Leslie M.

AU - Bernstein, Matthew A

AU - Petersen, Ronald Carl

AU - Weiner, Michael W.

AU - Knopman, David S

PY - 2011/12

Y1 - 2011/12

N2 - Objective: To empirically assess the concept that Alzheimer disease (AD) biomarkers significantly depart from normality in a temporally ordered manner. Design: Validation sample. Setting: Multisite, referral centers. Participants: A total of 401 elderly participants in the Alzheimer's Disease Neuroimaging Initiative who were cognitively normal, who had mild cognitive impairment, or who had AD dementia. We compared the proportions of 3 AD biomarker values (the Aβ42 level in cerebrospinal fluid [CSF], the total tau level in CSF, and the hippocampal volume adjusted for intracranial volume [hereafter referred to as the adjusted hippocampal volume]) that were abnormal as cognitive impairment worsened. Cut points demarcating normal vs abnormal for each biomarker were established by maximizing diagnostic accuracy in independent autopsy samples. Main Outcome Measures: Three AD biomarkers (ie, the CSF Aβ42 level, the CSF total tau level, and the adjusted hippocampal volume). Results: Within each clinical group of the entire sample (n=401), the CSF Aβ42 level was abnormal more often than was the CSF total tau level or the adjusted hippocampal volume. Among the 298 participants with bothbaseline and 12-month data, the proportion of participants with an abnormal Aβ42 level did not change from baseline to 12 months in any group. The proportion of participants with an abnormal total tau level increased from baseline to 12 months in cognitively normal participants (P=.05) but not in participants with mild cognitive impairment or AD dementia. For 209 participants with an abnormal CSF Aβ42 level at baseline, the percentage with an abnormal adjusted hippocampal volume but normal CSF total tau level increased from baseline to 12 months in participants with mild cognitive impairment. No change in the percentage of MCI participants with an abnormal total tau level was seen between baseline and 12 months. Conclusions: A reduction in the CSF Aβ42 level denotes a pathophysiological process that significantly departs from normality (ie, becomes dynamic) early, whereas the CSF total tau level and the adjusted hippocampal volume are biomarkers of downstream pathophysiological processes. The CSF total tau level becomes dynamic before the adjusted hippocampal volume, but the hippocampal volume is more dynamic in the clinically symptomatic mild cognitive impairment and AD dementia phases of the disease than is the CSF total tau level.

AB - Objective: To empirically assess the concept that Alzheimer disease (AD) biomarkers significantly depart from normality in a temporally ordered manner. Design: Validation sample. Setting: Multisite, referral centers. Participants: A total of 401 elderly participants in the Alzheimer's Disease Neuroimaging Initiative who were cognitively normal, who had mild cognitive impairment, or who had AD dementia. We compared the proportions of 3 AD biomarker values (the Aβ42 level in cerebrospinal fluid [CSF], the total tau level in CSF, and the hippocampal volume adjusted for intracranial volume [hereafter referred to as the adjusted hippocampal volume]) that were abnormal as cognitive impairment worsened. Cut points demarcating normal vs abnormal for each biomarker were established by maximizing diagnostic accuracy in independent autopsy samples. Main Outcome Measures: Three AD biomarkers (ie, the CSF Aβ42 level, the CSF total tau level, and the adjusted hippocampal volume). Results: Within each clinical group of the entire sample (n=401), the CSF Aβ42 level was abnormal more often than was the CSF total tau level or the adjusted hippocampal volume. Among the 298 participants with bothbaseline and 12-month data, the proportion of participants with an abnormal Aβ42 level did not change from baseline to 12 months in any group. The proportion of participants with an abnormal total tau level increased from baseline to 12 months in cognitively normal participants (P=.05) but not in participants with mild cognitive impairment or AD dementia. For 209 participants with an abnormal CSF Aβ42 level at baseline, the percentage with an abnormal adjusted hippocampal volume but normal CSF total tau level increased from baseline to 12 months in participants with mild cognitive impairment. No change in the percentage of MCI participants with an abnormal total tau level was seen between baseline and 12 months. Conclusions: A reduction in the CSF Aβ42 level denotes a pathophysiological process that significantly departs from normality (ie, becomes dynamic) early, whereas the CSF total tau level and the adjusted hippocampal volume are biomarkers of downstream pathophysiological processes. The CSF total tau level becomes dynamic before the adjusted hippocampal volume, but the hippocampal volume is more dynamic in the clinically symptomatic mild cognitive impairment and AD dementia phases of the disease than is the CSF total tau level.

UR - http://www.scopus.com/inward/record.url?scp=81755177047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81755177047&partnerID=8YFLogxK

U2 - 10.1001/archneurol.2011.183

DO - 10.1001/archneurol.2011.183

M3 - Article

C2 - 21825215

AN - SCOPUS:81755177047

VL - 68

SP - 1526

EP - 1535

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 12

ER -